Notably, emerging studies have suggested that GLP-1 receptor agonists may be associated with lower rates of certain obesity-related cancers in patients with type 2 diabetes, although such data are still limited.5,6 Despite these findings, the lack of robust evidence and specific guidelines for high-risk populations is worth noting. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.